A phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: Armed oncolytic adenovirus for the treatment of head and neck cancers

Abstract

These preliminary results showed that intratumoral administration of KH901 was feasible, well tolerated and associated with biological activity, further investigation of KH901, particularly in combination with systemic chemotherapy, was warranted.